GASL prize 2016 for CRC 841 scientist
22 January 2016
Dr. Dorothee Schwinge, PostDoc within CRC 841 project B3, is awarded the GASL Prize 2016. Der prize is endowed with 3,000 euros (funded by the YAEL foundation) and will be conferred today during the 32nd Annual Meeting of the German Association for the Study of the Liver (GASL) in Düsseldorf.
With the prize the GASL honours Schwinge’s Journal of Immunology publication “Testosterone Suppresses Hepatic Inflammation by the Downregulation of IL-17, CXCL-9, and CXCL-10 in a Mouse Model of Experimental Acute Cholangitis”. In this publication the scientists describe a new cholangitis model which allows to study the influence of gender on liver inflammation. Similar to autoimmune liver diseases in humans, the model is characterized by gender differences in susceptibility: while female animals become sick, male mice develop any symptoms. The scientists were able to show that the hormone testosterone has an important function. In female mice, the disease could be suppressed by doses of testosterone, males in contrast lose their protection follwoing castration. Obviously, the sex hormone suppresses the production of certain neurotransmitters, which in turn promote and activate inflammatory responses. A deeper understanding of the underlying molecular mechanisms could lead to new therapeutic approaches for patients with autoimmune liver diseases.
Schwinge D, Carambia A, Quaas A, Krech T, Wegscheid C, Tiegs G, Prinz I, Lohse AW, Herkel J, Schramm C
Testosterone Suppresses Hepatic Inflammation by the Downregulation of IL-17, CXCL-9, and CXCL-10 in a Mouse Model of Experimental Acute Cholangitis
J Immunol. 2015 Mar 15;194(6):2522-30. doi: 10.4049/jimmunol.1400076. Epub 2015 Feb 11.
Project B3 headed by Prof. Christoph Schramm: Role of regulatory T cells and TH17 cells for the pathogenesis and treatment of cholangitis
Primary sclerosing cholangitis, or PSC, is a rare, chronic, scarring disease of the bile ducts inside and outside the liver. It mainly affects young adults and leads to cirrhosis of the liver within 10 to 20 years. Although the disease is frequently fatal, its progress is largely unresearched. This situation hopefully changes in near future: Scientists and clinicians from Hamburg have set up the Clinical Research Unit 306 “Primary sclerosing cholangitis” to comprehensively understand and decipher this complex disease. The German Research Foundation decided December 2015 to support this research initiative with more than four million euros in the next three years. More>>